IDH2 and neoplasm: In this respect, it is important to note that our study was limited to diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology, because IDH-mutant astrocytic-appearing tumours with ATRX loss can be confidently diagnosed as astrocytic without the need for 1p/19q codeletion testing [21].